Navigation Links
Peregrine Pharmaceuticals Announces Four Upcoming Presentations at the American Association for Cancer Research 2008 Annual Meeting
Date:4/11/2008

TUSTIN, Calif., April 11 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing targeted therapies for the treatment of cancer and hepatitis C virus infection (HCV), today announced that the following preclinical abstracts will be the subject of oral and poster presentations at the 2008 Annual Meeting of the American Association for Cancer Research (AACR), being held April 12-16, 2008 in San Diego:

-- "Targeting mutant p53 protein and tumor vasculature: An effective

combination therapy for advanced breast tumors" (Abstract #2341, New

Targets 1: Mechanisms Session) - Poster session scheduled for Monday,

April 14, 2008 from 8:00 am to 12:00 pm.

-- "An immunocytokine that binds to phosphatidylserine generates an

effective cell-based tumor vaccine in mice" (Abstract #2841, Tumor

Vaccines Session) - Poster session scheduled for Monday, April 14,

2008 from 1:00 pm to 5:00 pm.

-- "Combination of a monoclonal anti-phosphatidylserine antibody with

docetaxel strongly inhibits the growth and metastasis of

hormone-refractory prostate cancers in mice" (Abstract #2551, New

Approaches to Biological Therapy Session) - Oral presentation

scheduled for Monday, April 14, 2008 at 2:10 pm.

-- "Antibody targeting of phosphatidylserine produces a cytokine

microenvironment that enhances innate anti-tumor immune responses"

(Abstract #4079, Immunoconjugates, Peptides, and Protein Therapeutics

Session) - Poster session scheduled for Tuesday, April 15, 2008 from

8:00 am to 12:00 pm.

Abstracts and information abou
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
2. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
3. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
4. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
5. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
6. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
7. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
8. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
9. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
10. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
11. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... Francisco, California (PRWEB) October 01, 2014 ... from the National Science Foundation to expand their bioCAD/CAM ... to build and modify DNA. The Small Business Innovation ... commercialize the “j5” technology under exclusive license from the ... Joint BioEnergy Institute , an LBNL laboratory that ...
(Date:9/30/2014)... a well-known optical phenomenon called thin-film interference, a ... the ability to "paint" ultra-thin coatings onto a ... making future, flexible electronic devices, creating advanced solar ... ships and spacecraft with extremely lightweight decorative logos. ... it becomes iridescent, revealing a myriad of colors ...
(Date:9/30/2014)... Shimadzu Scientific Instruments has released ... highly precise tool for measuring displacement in rubber ... 1000-mm maximum movement distance, the DSES-1000 can measure ... length of 10 mm. In addition, it achieves ... stroke and within +/- 100 µm below 50-mm ...
(Date:9/30/2014)... ROCKVILLE, Md. , Sept. 30, 2014 /PRNewswire/ ... "RegeneRx") today announced that it has received a ... Aging by Actin-Sequestering Peptides.  This patent includes claims ... and numerous other actin-sequestering peptides for these purposes.  ... About RegeneRx Biopharmaceuticals, Inc. ( www.regenerx.com ) ...
Breaking Biology Technology:TeselaGen Receives $750k NSF SBIR Phase II Award 2TeselaGen Receives $750k NSF SBIR Phase II Award 3Taking thin films to the extreme 2Shimadzu’s New Long-Travel Extensometer Increases Precision for Soft Material Testing 2RegeneRx Receives Canadian Patent for Inhibition or Reversal of Skin Aging 2
... 19, 2011 New Report Added in ... to 2020 - Programmable Logic Devices (PLD) and Application Specific ...   Published by  GBI Research . ... 2020 Programmable Logic Devices (PLD) and Application Specific Standard Product ...
... about how certain kinds of bacteria make energy and synthesize ... team of scientists led by Donald Bryant, the Ernest C. ... research professor in the Department of Chemistry and Biochemistry at ... the journal Science on 16 December 2011, is ...
... The efficiency of conventional solar cells could be ... of solar energy conversion led by chemist Xiaoyang Zhu ... and his team have discovered that it,s possible to ... of sunlight using an organic plastic semiconductor material. ...
Cached Biology Technology:ResearchMoz: Logic Integrated Circuit (IC) Market to 2020 - Programmable Logic Devices (PLD) and Application Specific Standard Product (ASSP) Dominate with a 78% Market Share 2ResearchMoz: Logic Integrated Circuit (IC) Market to 2020 - Programmable Logic Devices (PLD) and Application Specific Standard Product (ASSP) Dominate with a 78% Market Share 3ResearchMoz: Logic Integrated Circuit (IC) Market to 2020 - Programmable Logic Devices (PLD) and Application Specific Standard Product (ASSP) Dominate with a 78% Market Share 4Decades-old conclusion about energy-making pathway of cyanobacteria is corrected 2Decades-old conclusion about energy-making pathway of cyanobacteria is corrected 3Discovery of a 'dark state' could mean a brighter future for solar energy 2
(Date:9/30/2014)... Researchers of Ludwig-Maximilians-Universitaet (LMU) in Munich report that ... cells more sensitive to chemotherapeutic drugs. They have ... a new target for anti-tumor agents. , ... Professor Stephan Sieber of the Technische Universitt Mnchen ... a potential new weapon in the fight against ...
(Date:9/30/2014)... in German . ... to risky situations such as exposure to predators. Researchers ... in a long-term study on different populations of great ... and ambient temperature. High metabolic rates and low temperatures ... scenarios birds were more likely to approach potential predators. ...
(Date:9/30/2014)... People who suffer from asthma may think there,s ... asthma besides properly taking medications and avoiding allergic triggers. ... Annals of Allergy, Asthma and Immunology , the ... and Immunology (ACAAI), asthma sufferers can learn lessons about ... described in the Annals article improved her asthma once ...
Breaking Biology News(10 mins):Cancer therapy: Driving cancer cells to suicide 2Risky metabolism 2Asthma symptoms kicking up? Check your exposure to air pollution 2
... On Monday, August 17th at 1:30PM in Hensill Hall 113, ... AAAS in San Francisco will get to learn about the ... minds in the field. The symposium is called Good ... the Public. (Online link: http://www.sou.edu/aaaspd/2009SANFRANCISCO/Symposia09.html#15 ). As science ...
... another piece to the mounting body of evidence that ... arrest, "passive ventilation" significantly increases survival rates, compared to ... in an online edition of Annals of Emergency Medicine, ... cardiac arrest outside a hospital setting and were resuscitated ...
... 12, 2009) Research published online in the journal ... are associated with a 2.5-fold reduction in risk for neural ... brain and spinal cord, and the two most common NTDs ... Disease Control (CDC), an estimated 3,000 pregnancies in the U.S. ...
Cached Biology News:Science communication to take the stage at annual AAAS meeting in San Francisco 2Cardiac arrest resuscitation: Passive oxygen flow better than assisted ventilation 2Essential nutrient found in eggs may help lower risk of neural tube defects 2Essential nutrient found in eggs may help lower risk of neural tube defects 3
... pp65 Antigenemia Immunofluorescence Assay (IFA) is intended ... protein pp65 of CMV in isolated peripheral ... Erythrocyte Lysis Buffer - (Catalog ... of buffered ammonium chloride. (NH4CL) Fixation ...
ANTI NO-TRYPTOPHAN CONJUGATE...
ANTI DEOXY CORTICO...
... samples for freezing point determinations. Includes built-in printer, keypad, and software for ... RS-232 port. Microprocessor-controlled autocalibration. Two-step Calibration. ... ... ...
Biology Products: